CDX 1401

Drug Profile

CDX 1401

Alternative Names: CDX-1401; DEC-205/NY-ESO-1 vaccine - Celldex

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Gynaecological cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 06 Jul 2017 National Cancer Institute plans a phase I/II trial for Fallopian tube cancer (Recurrent, Second-line therapy or greater, Combination therapy),Ovarian cancer (Recurrent, Second-line therapy or greater, Combination therapy) and Peritoneal cancer (Recurrent, Second-line therapy or greater, Combination therapy) in USA (NCT03206047)
  • 03 Dec 2016 Accrued efficacy data from a phase I trial in Myelodysplastic syndromes and Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 29 Jul 2016 Case Comprehensive Cancer Center plans a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease) in USA (NCT02661100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top